{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:32:20Z","timestamp":1777415540812,"version":"3.51.4"},"reference-count":120,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Macular edema (ME) is a major complication of several vascular and inflammatory retinal diseases. Multiple mechanisms are implicated in its development and lead to visual impairment that could be reversible (the acute stages) or not reversible (long-standing ME). For this reason, an effective approach to the treatment of ME is of paramount importance in order to prevent irreversible damage of visual function. In this review, we discuss the management of ME and, in particular, current data of studies and clinical trials about drugs that have already been evaluated or are under investigation in the management of ME. Although several diseases could lead to the development of ME, we focus on the three main causes: diabetic retinopathy (DR), retinal vein occlusion (RVO), and uveitis. The introduction into clinical practice of anti-vascular endothelial growth factor injections (ranibizumab and aflibercept) and dexamethasone implants has revolutionized the treatment of ME secondary to DR and RVO. However, new drugs are needed in the treatment of resistant forms of ME secondary to DR and RVO. A fluocinolone acetonide implant has been approved by the US Food and Drug Administration for the treatment of diabetic ME but not for RVO. Furthermore, brolucizumab and abicipar pegol have been shown to be effective in preliminary studies and have the chance to be approved soon for diabetic ME treatment. In ME secondary to uveitis, a crucial role is played by corticosteroids and non-biologic immunomodulatory drugs. However, several new biologic agents are under investigation in different clinical trials and could be important new therapeutic options in cases with a low response to first-line therapy. However, only a few of these drugs will enter the market after proving their safety and efficacy. Only after that will we be able to offer a new therapeutic option to patients affected by uveitic ME.<\/ns4:p>","DOI":"10.12688\/f1000research.19198.1","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T04:25:06Z","timestamp":1565583906000},"page":"1413","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["Emerging therapies in the management of macular edema: a review"],"prefix":"10.12688","volume":"8","author":[{"given":"Riccardo","family":"Sacconi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Giuffr\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Corbelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Querques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3238-9682","authenticated-orcid":false,"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2019,8,12]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"556-64","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy.","volume":"35","author":"J Yau","year":"2012","journal-title":"Diabetes Care."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"313-9.e1","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia.","volume":"117","author":"S Rogers","year":"2010","journal-title":"Ophthalmology."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"332-6","DOI":"10.1136\/bjo.80.4.332","article-title":"Causes and frequency of blindness in patients with intraocular inflammatory disease.","volume":"80","author":"A Rothova","year":"1996","journal-title":"Br J Ophthalmol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"20-68","DOI":"10.1016\/j.preteyeres.2017.10.006","article-title":"Mechanisms of macular edema: Beyond the surface.","volume":"63","author":"A Daruich","year":"2018","journal-title":"Prog Retin Eye Res."},{"key":"ref-5","first-page":"149-56","article-title":"Experimental macular edema of commotio retinae: preliminary report.","volume":"27","author":"T Kohno","year":"1983","journal-title":"Jpn J Ophthalmol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"505-11","DOI":"10.1016\/0039-6257(84)90233-9","article-title":"Pathology of human cystoid macular edema.","volume":"28 Suppl","author":"M Yanoff","year":"1984","journal-title":"Surv Ophthalmol."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"249-54","DOI":"10.1038\/eye.1990.36","article-title":"The blood-brain interface.","volume":"4","author":"M Bradbury","year":"1990","journal-title":"Eye (Lond)."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"303-9","DOI":"10.1038\/eye.1990.41","article-title":"Permeability of ocular vessels and transport across the blood-retinal-barrier.","volume":"4","author":"P T\u00f6rnquist","year":"1990","journal-title":"Eye (Lond)."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"77-88","DOI":"10.1007\/s10456-007-9065-1","article-title":"Development of the retinal vasculature.","volume":"10","author":"M Fruttiger","year":"2007","journal-title":"Angiogenesis."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"19-48","DOI":"10.1016\/j.preteyeres.2013.02.001","article-title":"Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions.","volume":"34","author":"I Klaassen","year":"2013","journal-title":"Prog Retin Eye Res."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"54-9","DOI":"10.1016\/j.lfs.2016.08.001","article-title":"The importance of glial cells in the homeostasis of the retinal microenvironment and their pivotal role in the course of diabetic retinopathy.","volume":"162","author":"F Sorrentino","year":"2016","journal-title":"Life Sci."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"183-95","DOI":"10.2147\/opth.s5901","article-title":"The outer limiting membrane (OLM) revisited: clinical implications.","volume":"4","author":"S Omri","year":"2010","journal-title":"Clin Ophthalmol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"e649-e653","DOI":"10.1111\/aos.12735","article-title":"Quantifying metamorphopsia in patients with diabetic macular oedema and other macular abnormalities.","volume":"93","author":"A Achiron","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"1915-22","DOI":"10.1097\/IAE.0b013e318285cc0c","article-title":"Therapeutic interventions for macular diseases show characteristic effects on near and distance visual function.","volume":"33","author":"M Munk","year":"2013","journal-title":"Retina."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"774-80","DOI":"10.1097\/IAE.0b013e3181c2e0d6","article-title":"Correlation between visual acuity and foveal microstructural changes in diabetic macular edema.","volume":"30","author":"T Otani","year":"2010","journal-title":"Retina."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"519-28","DOI":"10.1016\/j.ophtha.2008.10.001","article-title":"Foveal microstructure and visual acuity after retinal detachment repair: imaging analysis by Fourier-domain optical coherence tomography.","volume":"116","author":"T Wakabayashi","year":"2009","journal-title":"Ophthalmology."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"2560-70","DOI":"10.2337\/db14-0782","article-title":"Neural Retinal Disorganization as a Robust Marker of Visual Acuity in Current and Resolved Diabetic Macular Edema.","volume":"64","author":"J Sun","year":"2015","journal-title":"Diabetes."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"1684-90","DOI":"10.1136\/bjophthalmol-2017-311240","article-title":"Optical coherence tomography angiography in pseudophakic cystoid macular oedema compared to diabetic macular oedema: qualitative and quantitative evaluation of retinal vasculature.","volume":"102","author":"R Sacconi","year":"2018","journal-title":"Br J Ophthalmol."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"1536-46","DOI":"10.1016\/S0161-6420(93)31447-8","article-title":"Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study.","volume":"100","author":"J Gass","year":"1993","journal-title":"Ophthalmology."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"49-77","DOI":"10.1016\/j.preteyeres.2012.11.002","article-title":"Macular telangiectasia type 2.","volume":"34","author":"P Charbel Issa","year":"2013","journal-title":"Prog Retin Eye Res."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"137-46","DOI":"10.1016\/j.ajo.2017.10.009","article-title":"The Expanded Spectrum of Perifoveal Exudative Vascular Anomalous Complex.","volume":"184","author":"R Sacconi","year":"2017","journal-title":"Am J Ophthalmol."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"102-4","DOI":"10.1038\/eye.2012.228","article-title":"Topical dorzolamide therapy for taxane-related macular oedema.","volume":"27","author":"J Ehlers","year":"2013","journal-title":"Eye (Lond)."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"1003-12","DOI":"10.1038\/eye.2015.82","article-title":"MEK inhibitors: A new class of chemotherapeutic agents with ocular toxicity.","volume":"29","author":"K Duncan","year":"2015","journal-title":"Eye (Lond)."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"260-2","DOI":"10.1097\/ICB.0000000000000487","article-title":"Bilateral serous macular detachment in a patient with nephrotic syndrome.","volume":"12","author":"A Bilge","year":"2018","journal-title":"Retin Cases Brief Rep."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"1275-87","DOI":"10.1001\/jamaophthalmol.2013.4056","article-title":"Paracentral acute middle maculopathy: a new variant of acute macular neuroretinopathy associated with retinal capillary ischemia.","volume":"131","author":"D Sarraf","year":"2013","journal-title":"JAMA Ophthalmol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"734-42","DOI":"10.1038\/eye.2017.295","article-title":"Response of central serous chorioretinopathy evaluated by multimodal retinal imaging.","volume":"32","author":"R Sacconi","year":"2018","journal-title":"Eye (Lond)."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"1375-94","DOI":"10.1016\/j.ophtha.2015.03.024","article-title":"Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets.","volume":"122","author":"A Das","year":"2015","journal-title":"Ophthalmology."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"615-25","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.","volume":"118","author":"P Mitchell","year":"2011","journal-title":"Ophthalmology."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"789-801","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.","volume":"119","author":"Q Nguyen","year":"2012","journal-title":"Ophthalmology."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"2013-22","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.","volume":"120","author":"D Brown","year":"2013","journal-title":"Ophthalmology."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"1193-203","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.","volume":"372","author":"J Wells","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"2376-85","DOI":"10.1016\/j.ophtha.2016.07.032","article-title":"Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.","volume":"123","author":"J Heier","year":"2016","journal-title":"Ophthalmology."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"636-43","DOI":"10.1097\/ICU.0000000000000424","article-title":"Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.","volume":"28","author":"S Cai","year":"2017","journal-title":"Curr Opin Ophthalmol."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"245-50","DOI":"10.3928\/23258160-20180329-06","article-title":"Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes.","volume":"49","author":"G de Andrade","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"1387-90","DOI":"10.1136\/bjophthalmol-2017-311591","article-title":"Two-year outcomes of intravitreal ziv-aflibercept.","volume":"102","author":"A Mansour","year":"2018","journal-title":"Br J Ophthalmol."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"1904-14","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.","volume":"121","author":"D Boyer","year":"2014","journal-title":"Ophthalmology."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"1827-33","DOI":"10.1016\/j.ophtha.2010.12.034","article-title":"Economic considerations of macular edema therapies.","volume":"118","author":"W Smiddy","year":"2011","journal-title":"Ophthalmology."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"2004-12","DOI":"10.1016\/j.ophtha.2013.02.019","article-title":"Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study.","volume":"120","author":"G Lang","year":"2013","journal-title":"Ophthalmology."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"421-2","DOI":"10.1136\/bjophthalmol-2013-303352","article-title":"Cost-effectiveness of treatments for diabetic macular oedema: should we pay more attention to the appraisal and reporting of economic evaluations?","volume":"98","author":"G Virgili","year":"2014","journal-title":"Br J Ophthalmol."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"2125-32","DOI":"10.1016\/j.ophtha.2012.04.030","article-title":"Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.","volume":"119","author":"P Campochiaro","year":"2012","journal-title":"Ophthalmology."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"1707-15","DOI":"10.1038\/eye.2017.125","article-title":"Real-world experience with 0.2\u2009\u03bcg\/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom.","volume":"31","author":"C Bailey","year":"2017","journal-title":"Eye (Lond)."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12886-018-0726-1","article-title":"Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien\u2122) at 2 years.","volume":"18","author":"W Fusi-Rubiano","year":"2018","journal-title":"BMC Ophthalmol."},{"key":"ref-43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.","author":"P Dugel","year":"2019","journal-title":"Ophthalmology."},{"key":"ref-44","article-title":"Study of efficacy and safety of Brolucizumab vs. Aflibercept in Patients with visual impairment due to diabetic macular edema (KESTREL)"},{"key":"ref-45","article-title":"A multicenter, double masked phase 2 clinical trial evaluating abicipar pegol for diabetic macular edema","author":"T Hassan","year":"2016"},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"1480-7","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.","volume":"331","author":"L Aiello","year":"1994","journal-title":"N Engl J Med."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"1161-9","DOI":"10.1016\/s0092-8674(00)81812-7","article-title":"Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning.","volume":"87","author":"S Davis","year":"1996","journal-title":"Cell."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"55-60","DOI":"10.1126\/science.277.5322.55","article-title":"Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.","volume":"277","author":"P Maisonpierre","year":"1997","journal-title":"Science."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"1721-7","DOI":"10.1074\/jbc.M208550200","article-title":"Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats.","volume":"278","author":"U Fiedler","year":"2003","journal-title":"J Biol Chem."},{"key":"ref-50","article-title":"A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)"},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"2143082","DOI":"10.1155\/2016\/2143082","article-title":"Intravitreal Conbercept Injection with and without Grid Laser Photocoagulation in the Treatment of Diffuse Diabetic Macular Edema in Real-Life Clinical Practice.","volume":"2016","author":"Y Xu","year":"2016","journal-title":"J Ophthalmol."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12886-017-0554-8","article-title":"Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study.","volume":"17","author":"Y Xu","year":"2017","journal-title":"BMC Ophthalmol."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"204-10","DOI":"10.1007\/s11095-008-9718-9","article-title":"The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization.","volume":"26","author":"M Zhang","year":"2009","journal-title":"Pharm Res."},{"key":"ref-54","first-page":"37-49","article-title":"Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys.","volume":"14","author":"M Zhang","year":"2008","journal-title":"Mol Vis."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"2131-9","DOI":"10.1007\/s00417-013-2392-6","article-title":"Anti-angiogenic effect of KH902 on retinal neovascularization.","volume":"251","author":"F Wang","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"ref-56","article-title":"Safety and efficacy by multiple injection of KH902 in patients with diabetic macular edema (DME) (Frontier-1)"},{"key":"ref-57","article-title":"Safety and efficacy study of conbercept in diabetic macular edema (DME) (Sailing)"},{"key":"ref-58","article-title":"A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema"},{"key":"ref-59","article-title":"Topline results from prospective, double-masked, placebo controlled phase 2b clinical study evaluating Luminate in patients with diabetic macular edema","author":"P Kaiser","year":"2017"},{"key":"ref-60","article-title":"Human phase 2 clinical studies update. DEL MAR Phase 2B","author":"D Boyer","year":"2017"},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"233-9","DOI":"10.1097\/ICU.0000000000000143","article-title":"Advances in drug delivery to the posterior segment.","volume":"26","author":"W Pearce","year":"2015","journal-title":"Curr Opin Ophthalmol."},{"key":"ref-62","article-title":"Suprachoroidal triamcinolone acetonide with and without intravitreal aflibercept for diabetic macular edema: Phase 1\/2 HULK study","author":"C Wykoff","year":"2017"},{"key":"ref-63","article-title":"Suprachoroidal CLS-TA with intravitreal aflibercept versus aflibercept alone in subject with diabetic macular edema (TYBEE).","author":"I Clearside Biomedical,"},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"1-25","DOI":"10.1016\/j.preteyeres.2014.04.001","article-title":"Ocular vascular occlusive disorders: natural history of visual outcome.","volume":"41","author":"S Hayreh","year":"2014","journal-title":"Prog Retin Eye Res."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"278-84","DOI":"10.1136\/bjophthalmol-2012-301504","article-title":"VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study.","volume":"97","author":"F Holz","year":"2013","journal-title":"Br J Ophthalmol."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"1024-32","DOI":"10.1016\/j.ophtha.2012.01.042","article-title":"Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.","volume":"119","author":"D Boyer","year":"2012","journal-title":"Ophthalmology."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"1134-1146.e3","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.","volume":"117","author":"J Haller","year":"2010","journal-title":"Ophthalmology."},{"key":"ref-68","article-title":"Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN)."},{"key":"ref-69","article-title":"Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR)."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"987-90","DOI":"10.1080\/09273948.2018.1529466","article-title":"Uveitic Macular Edema.","volume":"26","author":"E Cunningham","year":"2018","journal-title":"Ocul Immunol Inflamm."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"263-70","DOI":"10.1097\/00005792-200107000-00005","article-title":"Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center.","volume":"80","author":"B Bodaghi","year":"2001","journal-title":"Medicine (Baltimore)."},{"key":"ref-72","doi-asserted-by":"crossref","first-page":"509-17","DOI":"10.4155\/cli.15.1","article-title":"Uveitic macular edema: A stepladder treatment paradigm.","volume":"5","author":"J Preble","year":"2015","journal-title":"Clinical Investigation."},{"key":"ref-73","doi-asserted-by":"publisher","first-page":"667-80","DOI":"10.2147\/DDDT.S166092","article-title":"Update in treatment of uveitic macular edema.","volume":"13","author":"S Koronis","year":"2019","journal-title":"Drug Des Devel Ther."},{"key":"ref-74","doi-asserted-by":"publisher","first-page":"277-83","DOI":"10.4103\/0301-4738.114099","article-title":"Medical management of uveitis - current trends.","volume":"61","author":"K Babu","year":"2013","journal-title":"Indian J Ophthalmol."},{"key":"ref-75","doi-asserted-by":"publisher","first-page":"757-73","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative.","volume":"125","author":"A Dick","year":"2018","journal-title":"Ophthalmology."},{"key":"ref-76","doi-asserted-by":"publisher","first-page":"2993-3002","DOI":"10.1167\/iovs.13-12660","article-title":"Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study.","volume":"55","author":"J Sheppard","year":"2014","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"ref-77","doi-asserted-by":"publisher","first-page":"66-9","DOI":"10.1038\/eye.1994.12","article-title":"Orbital floor steroid injections in the treatment of uveitis.","volume":"8","author":"P Riordan-Eva","year":"1994","journal-title":"Eye (Lond)."},{"key":"ref-78","first-page":"385-91","article-title":"Posterior sub-Tenon's injections of corticosteroids in uveitis patients with cystoid macular edema.","volume":"32","author":"T Jennings","year":"1988","journal-title":"Jpn J Ophthalmol."},{"key":"ref-79","first-page":"71-6","article-title":"Posterior sub-Tenon injections of repository corticosteroids in uveitis patients with cystoid macular edema.","volume":"39","author":"K Yoshikawa","year":"1995","journal-title":"Jpn J Ophthalmol."},{"key":"ref-80","doi-asserted-by":"publisher","first-page":"139-49","DOI":"10.1016\/j.survophthal.2007.12.005","article-title":"Intravitreal steroids for macular edema: the past, the present, and the future.","volume":"53","author":"M Cunningham","year":"2008","journal-title":"Surv Ophthalmol."},{"key":"ref-81","doi-asserted-by":"publisher","first-page":"545-53","DOI":"10.1001\/archophthalmol.2010.339","article-title":"Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis.","volume":"129","author":"C Lowder","year":"2011","journal-title":"Arch Ophthalmol."},{"key":"ref-82","doi-asserted-by":"publisher","first-page":"685-692","DOI":"10.3109\/09273948.2016.1160130","article-title":"Intravitreal Dexamethasone Implant for the Treatment of Macular Edema in Chronic Non-infectious Uveitis.","volume":"25","author":"A Tsang","year":"2017","journal-title":"Ocul Immunol Inflamm."},{"key":"ref-83","doi-asserted-by":"publisher","first-page":"1871-6","DOI":"10.1016\/j.ophtha.2014.04.012","article-title":"Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation.","volume":"121","author":"J Cao","year":"2014","journal-title":"Ophthalmology."},{"key":"ref-84","doi-asserted-by":"publisher","first-page":"1778-85","DOI":"10.1097\/IAE.0000000000001001","article-title":"Safety and Efficacy of Intravitreal Dexamethasone Implants in the Management of Macular Edema Secondary to Infectious Uveitis.","volume":"36","author":"A Fonollosa","year":"2016","journal-title":"Retina."},{"key":"ref-85","doi-asserted-by":"publisher","first-page":"884-92","DOI":"10.1080\/09273948.2017.1400074","article-title":"The Role of Dexamethasone Implant in the Management of Tubercular Uveitis.","volume":"26","author":"A Agarwal","year":"2018","journal-title":"Ocul Immunol Inflamm."},{"key":"ref-86","doi-asserted-by":"publisher","first-page":"550-561.e10","DOI":"10.1016\/j.ajo.2009.11.019","article-title":"The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics.","volume":"149","author":"J Kempen","year":"2010","journal-title":"Am J Ophthalmol."},{"key":"ref-87","article-title":"Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Posterior Uveitis."},{"key":"ref-88","doi-asserted-by":"publisher","first-page":"492-513","DOI":"10.1016\/s0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.","volume":"130","author":"D Jabs","year":"2000","journal-title":"Am J Ophthalmol."},{"key":"ref-89","doi-asserted-by":"publisher","first-page":"470-90","DOI":"10.1016\/j.survophthal.2004.06.002","article-title":"Macular edema.","volume":"49","author":"P Tranos","year":"2004","journal-title":"Surv Ophthalmol."},{"key":"ref-90","doi-asserted-by":"publisher","first-page":"161-5","DOI":"10.1080\/09273940802204519","article-title":"Azathioprine in the management of autoimmune uveitis.","volume":"16","author":"P Pacheco","year":"2008","journal-title":"Ocul Immunol Inflamm."},{"key":"ref-91","doi-asserted-by":"publisher","first-page":"797-801","DOI":"10.1016\/j.ophtha.2008.10.033","article-title":"Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema.","volume":"116","author":"S Taylor","year":"2009","journal-title":"Ophthalmology."},{"key":"ref-92","doi-asserted-by":"publisher","first-page":"2149-54","DOI":"10.1097\/IAE.0b013e31828ac07d","article-title":"Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis.","volume":"33","author":"S Taylor","year":"2013","journal-title":"Retina."},{"key":"ref-93","doi-asserted-by":"publisher","first-page":"481-6","DOI":"10.1097\/ICU.0b013e3282f03d42","article-title":"Biologics in the treatment of uveitis.","volume":"18","author":"F Imrie","year":"2007","journal-title":"Curr Opin Ophthalmol."},{"key":"ref-94","doi-asserted-by":"publisher","first-page":"87-91","DOI":"10.1136\/bjophthalmol-2014-305535","article-title":"Mycophenolic acid in the treatment of birdshot chorioretinopathy: long-term follow-up.","volume":"99","author":"D Doycheva","year":"2014","journal-title":"Br J Ophthalmol."},{"key":"ref-95","doi-asserted-by":"publisher","first-page":"138-46","DOI":"10.1016\/s0002-9394(14)76692-9","article-title":"Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis.","volume":"112","author":"R Nussenblatt","year":"1991","journal-title":"Am J Ophthalmol."},{"key":"ref-96","doi-asserted-by":"publisher","first-page":"1000-6","DOI":"10.1016\/j.ophtha.2007.01.026","article-title":"Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis.","volume":"114","author":"A Hogan","year":"2007","journal-title":"Ophthalmology."},{"key":"ref-97","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1869-5760-3-32","article-title":"Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study.","volume":"3","author":"Q Nguyen","year":"2013","journal-title":"J Ophthalmic Inflamm Infect."},{"key":"ref-98","first-page":"T3","article-title":"The Effect of Different Dosing Schedules of Intravitreal Sirolimus, a Mammalian Target of Rapamycin (mTOR) Inhibitor, in the Treatment of Non-Infectious Uveitis (An American Ophthalmological Society Thesis).","volume":"114","author":"Q Nguyen","year":"2016","journal-title":"Trans Am Ophthalmol Soc."},{"key":"ref-99","doi-asserted-by":"publisher","first-page":"577-84","DOI":"10.1097\/01.ftd.0000245377.93401.39","article-title":"Sirolimus--challenging current perspectives.","volume":"28","author":"I Buhaescu","year":"2006","journal-title":"Ther Drug Monit."},{"key":"ref-100","doi-asserted-by":"publisher","first-page":"47-55","DOI":"10.1080\/09286580701585892","article-title":"Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.","volume":"15","author":"J Kempen","year":"2008","journal-title":"Ophthalmic Epidemiol."},{"key":"ref-101","doi-asserted-by":"publisher","first-page":"403-14","DOI":"10.3109\/09273940903072443","article-title":"Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience.","volume":"17","author":"S Sharma","year":"2009","journal-title":"Ocul Immunol Inflamm."},{"key":"ref-102","doi-asserted-by":"publisher","first-page":"1575-81","DOI":"10.1016\/j.ophtha.2012.02.018","article-title":"Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.","volume":"119","author":"M D\u00edaz-Llopis","year":"2012","journal-title":"Ophthalmology."},{"key":"ref-103","doi-asserted-by":"publisher","first-page":"633-40","DOI":"10.1007\/s00417-013-2552-8","article-title":"Anti-TNF-\u03b1 agents for refractory cystoid macular edema associated with noninfectious uveitis.","volume":"252","author":"M Schaap-Fogler","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"ref-104","doi-asserted-by":"publisher","first-page":"1612-6","DOI":"10.1016\/j.ophtha.2009.12.011","article-title":"Intravitreal adalimumab for refractory uveitis-related macular edema.","volume":"117","author":"S Androudi","year":"2010","journal-title":"Ophthalmology."},{"key":"ref-105","doi-asserted-by":"publisher","first-page":"628-31","DOI":"10.1089\/jop.2011.0199","article-title":"Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis.","volume":"28","author":"M Farvardin","year":"2012","journal-title":"J Ocul Pharmacol Ther."},{"key":"ref-106","doi-asserted-by":"publisher","first-page":"648-50","DOI":"10.1016\/j.ajo.2004.04.066","article-title":"Infliximab for chronic cystoid macular edema associated with uveitis.","volume":"138","author":"N Markomichelakis","year":"2004","journal-title":"Am J Ophthalmol."},{"key":"ref-107","first-page":"320-1","article-title":"Golimumab treatment for complicated uveitis.","volume":"31","author":"E Miserocchi","year":"2013","journal-title":"Clin Exp Rheumatol."},{"key":"ref-108","doi-asserted-by":"publisher","first-page":"90-5","DOI":"10.3109\/09273948.2013.844265","article-title":"Long-term treatment with golimumab for severe uveitis.","volume":"22","author":"E Miserocchi","year":"2014","journal-title":"Ocul Immunol Inflamm."},{"key":"ref-109","doi-asserted-by":"publisher","first-page":"1107-1117","DOI":"10.1136\/annrheumdis-2018-213131","article-title":"Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative.","volume":"77","author":"T Constantin","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"ref-110","doi-asserted-by":"publisher","first-page":"215-20","DOI":"10.3109\/09273948.2015.1099680","article-title":"Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment.","volume":"25","author":"C Deuter","year":"2017","journal-title":"Ocul Immunol Inflamm."},{"key":"ref-111","doi-asserted-by":"publisher","first-page":"1361-70","DOI":"10.1097\/IAE.0000000000001690","article-title":"Twenty-Four Month Follow-Up of Tocilizumab Therapy for Refractory Uveitis-Related Macular Edema.","volume":"38","author":"M Mesquida","year":"2018","journal-title":"Retina."},{"key":"ref-112","doi-asserted-by":"publisher","first-page":"246-52","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).","volume":"13","author":"F Davatchi","year":"2010","journal-title":"Int J Rheum Dis."},{"key":"ref-113","doi-asserted-by":"publisher","first-page":"782-6","DOI":"10.1136\/bjophthalmol-2015-306790","article-title":"Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis.","volume":"100","author":"E Miserocchi","year":"2016","journal-title":"Br J Ophthalmol."},{"key":"ref-114","doi-asserted-by":"publisher","first-page":"706-11","DOI":"10.3899\/jrheum.140410","article-title":"Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis.","volume":"42","author":"C Tappeiner","year":"2015","journal-title":"J Rheumatol."},{"key":"ref-115","doi-asserted-by":"publisher","first-page":"307-8; author reply 308","DOI":"10.1002\/acr.20359","article-title":"Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al.","volume":"63","author":"M Elhai","year":"2011","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"ref-116","doi-asserted-by":"publisher","first-page":"297-300","DOI":"10.1007\/s00417-010-1523-6","article-title":"Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis.","volume":"249","author":"N Kenawy","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"ref-117","article-title":"Abatacept in the Treatment of Uveitis."},{"key":"ref-118","doi-asserted-by":"publisher","first-page":"1023-33","DOI":"10.1080\/09273948.2017.1421233","article-title":"Use of Gevokizumab in Patients with Beh\u00e7et's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study.","volume":"26","author":"I Tugal-Tutkun","year":"2018","journal-title":"Ocul Immunol Inflamm."},{"key":"ref-119","article-title":"Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)."},{"key":"ref-120","article-title":"Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis (Humboldt)."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/8-1413\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-1413\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-1413\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T04:55:11Z","timestamp":1565585711000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/8-1413\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,12]]},"references-count":120,"URL":"https:\/\/doi.org\/10.12688\/f1000research.19198.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.21038.r51942","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.21038.r51943","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,12]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/8-1413\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.21038.r51943, Andrew Chang, Sydney Institute of Vision Science, Sydney, NSW, Australia, 12 Aug 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1413\/v1#referee-response-51943","order":0,"name":"referee-response-51943","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.21038.r51942, Akitaka Tsujikawa, Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan, 12 Aug 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1413\/v1#referee-response-51942","order":1,"name":"referee-response-51942","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}